A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
Not yet recruiting · NCT07349641 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Endometrial Hyperplasia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Urogenital Diseases, female reproductive system disorder, uterine disorder | Not yet recruiting | Phase 2 | 2026-08-26 | NCT07349641 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Lyndon Baines Johnson General Hospital | Houston | United States | 36 |
| Northwestern University | Chicago | United States | 727 |
| UT MD Anderson Cancer Center | Houston | United States | 204 |